Measurement of cerebral expression of metabotropic glutamate receptor subtype 5 in autism spectrum disorder and fragile X syndrome

Legends. Measurement of cerebral expression of metabotropic glutamate receptor subtype 5 in autism spectrum disorder and fragile X syndrome Table S1. Concomitant medications of participants from the Institute for Neurodegenerative Disorders (IND) Table S2. Demographic and clinical characteristics of participants from the Institute for Neurodegenerative Disorders (IND) Table S3. Demographic and clinical characteristics of participants from the Johns Hopkins University (JHU) Table S4. Genetic and psychological assessments of participants from the Institute for Neurodegenerative Disorders (IND) Table S5. Genetic and psychological assessments of participants from the Johns Hopkins University (JHU) Table S6. Fragile X Mental Retardation Protein (FMRP) in nanogram per microgram total protein for ten healthy people with typical development (TD) with normal CGG repeat sizes [range (20, 37)] utilizing the same analyses as the other participants Table S7. Positron emission tomography (PET) data and analyses for participants from the Institute for Neurodegenerative Disorders (IND) Table S8. Positron emission tomography (PET) data and analysis of participants from the Johns Hopkins University (JHU) The authors thank Flora Tassone, Ph.D., Department of Biochemistry and Molecular Medicine, School of Medicine, UC Davis Health, Sacramento, California, for providing genetic and protein data about participants.This research was made possible by a Radiology BRidge/Development Funding Initiative to STimulate and Advance Research (RAD BriteStar Bridge) Award from the Johns Hopkins University School of Medicine, Baltimore, Maryland, to JRB; and the Intellectual andDevelopmental Disabilities Research Center (U54 HD079123), Kennedy Krieger Institute, Johns Hopkins Medical Institutions. Baltimore, Maryland, to JRB